Oncotarget

In The News - Press Releases


Oncotarget: BRCA1 mRNA expression in breast and colorectal cancer


FOR IMMEDIATE RELEASE
2021-09-28

Oncotarget published "Opposing effects of BRCA1 mRNA expression on patient survival in breast and colorectal cancer and variations among African American, Asian, and younger patients" which reported that LMNB2 is a chromatin remodeling protein that also plays a role in eukaryotic cell proliferation by organizing the nuclear membrane during mitosis.

High expression of LMNB2 in CRC tumors correlates with worse disease-free cumulative and overall survival, and that knocking out the LMNB2 gene allowed for the development of CRC tumors through a mechanism that involved silencing of p21 expression. In line with this, these authors found that young CRC patients, who tend to express high levels of BRCA1 in their tumors, also tend to express low levels of p21 and this may be due to simultaneous high expression of LMNB2.

Dr. Wafik S. El-Deiry from The Brown University as well as The Lifespan Health System said, "Breast cancer (BC) is the most common cancer in women besides nonmelanoma skin cancer".

12% of women will be diagnosed in their lifetime and the 5-year survival rate is as low as 28% once BC becomes metastatic. There are five molecular subtypes of BC which differ in their molecular presentation: luminal A hormone receptor, luminal B, triple-negative, HER2-enriched, and normal-like, which is similar to luminal A.

Triple-negative breast cancer can be further classified into:

basal-like 1,
basal-like 2,
Immunomodulatory,
Mesenchymal,
mesenchymal-stem like,
luminal androgen receptor, or
Unstable

Figure 5: TOP2A and ATAD5 mRNA expression correlates with BRCA1 mRNA expression in BC and CRC, whereas LMNB2 expression only correlates with BRCA1 expression in CRC. The top 100 genes whose expression correlated to BRCA1 expression were selected for BC and CRC and plotted on a scatter plot of Spearman's correlation with BRCA1 in BC versus CRC (A). TOP2A (B) and ATAD5 (C) mRNA expression correlates with BRCA1 mRNA expression across BC and CRC. LMNB2 mRNA expression correlates with BRCA1 mRNA expression only in CRC (D).

There is much interest in the field of cancer research regarding development of biomarkers to individualize treatment of existing therapies.

There is much interest in the field of cancer research regarding development of biomarkers to individualize treatment of existing therapies

Establishing and validating prognostic biomarkers can allow physicians and patients to make informed decisions that limit exposure of patients to unnecessary treatment and/or ensure that high-risk patients get the treatment they need. Some biomarkers exist for BC and CRC patients. BRCA1 is mutated in less than 1–7% of BC tumors when patients are not selected for family history, but when altered it is a robust biomarker for BC susceptibility with mutation carriers having a lifetime risk of up to 85% for BC.

BRCA1 mutations also predict worse overall survival compared to patients harboring wild-type BRCA1 tumors. BRCA1 mutations in CRC often result in loss of heterozygosity, have been found in almost 50% of sporadic cases, and offer similar utility as a biomarker for worse outcomes although conflicting results have been reported.

The El-Deiry Research Team concluded in their Oncotarget Research Output that surprisingly, there were no genes that correlated with BRCA1 mRNA expression uniquely in BC, but there were several genes that correlated with BRCA1 expression uniquely in CRC. LMNB2 is a chromatin remodeling protein that also plays a role in eukaryotic cell proliferation by organizing the nuclear membrane during mitosis. Despite this, the authors found that high BRCA1 mRNA levels correlate with better outcomes in CRC.

Sign up for free Altmetric alerts about this article

DOI - https://doi.org/10.18632/oncotarget.28082

Full text - https://www.oncotarget.com/article/28082/text/

Correspondence to - Wafik S. El-Deiry - wafik@brown.edu

Keywords - breast cancer, colorectal cancer, BRCA1, biomarker, early onset

About Oncotarget

Oncotarget is a biweekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957x105



Copyright © 2021 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC